Novo Nordisk Market Cap 2010-2022 | NVO

Novo Nordisk market cap history and chart from 2010 to 2022. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Novo Nordisk market cap as of March 24, 2023 is $338.49B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $338.495B $25.059B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $393.586B 14.88
Eli Lilly (LLY) United States $316.107B 41.89
AbbVie (ABBV) United States $273.971B 11.15
Merck (MRK) United States $264.598B 13.93
Pfizer (PFE) United States $226.792B 6.11
Novartis AG (NVS) Switzerland $182.562B 13.50